Development
Pfizer's berobenatide demonstrates nearly 16% weight loss in Phase IIb obesity trial data
Pfizer (NYSE: PFE) presented detailed Phase IIb data at the American Diabetes Association's 86th Scientific Sessions showing that berobenatide (PF-3944;...
Bayer posts Phase III data showing Kerendia's kidney benefit in non-diabetic CKD
Bayer's finerenone (Kerendia), a non-steroidal mineralocorticoid receptor antagonist, delivered statistically significant improvements in kidney function...
Otsuka's Voyxact on course for full approval in IgA nephropathy after positive Phase III
Twelve-month eGFR data from the Phase III VISIONARY trial of sibeprenlimab (Voyxact) in IgA nephropathy show that Otsuka's anti-APRIL monoclonal antibody...
Kexing's launches first-in-human testing for dual VEGF-Ang-2 BsAb in wAMD
China-based Kexing Biopharm has dosed the first subject in a Phase I clinical trial of GB10, a bispecific antibody targeting both VEGF and Angiopoietin-2...
ADC Therapeutics' Zynlonta plus rituximab meets Phase III endpoint in DLBCL, but safety concerns emerge
Switzerland-based ADC Therapeutics SA (NYSE: ADCT) reported that loncastuximab tesirine-lpyl (Zynlonta) combined with rituximab met the primary endpoint of...
Juncell Therapeutics' nolgileucel meets primary endpoint in Phase II advanced melanoma trial
China-based Juncell Therapeutics reported that nolgileucel (GC101), its autologous tumor-infiltrating lymphocyte therapy, met the primary endpoint in a...
Cardiff Oncology's onvansertib shows 72% response rate in first-line RAS-mutated mCRC
San Diego-based Cardiff Oncology (Nasdaq: CRDF) reported that onvansertib, an oral PLK1 inhibitor, produced a confirmed objective response rate of 72.2% in...
Legend Bio posts early data for CD19/CD20 in vivo CAR-T showing 100% response rate in NHL
Legend Biotech (Nasdaq: LEGN) reported a 100% objective response rate in six evaluable patients treated at the higher dose level of LB2501, its...
Cumberland's ifetroban shows ability to block tumor metastasis in Phase IIa trial
Nashville-based Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) reported that ifetroban, its thromboxane A2 receptor antagonist, met the primary safety...
Karyopharm's XPO1 plus JAK inhibitor regimen both hits and misses in Phase III myelofibrosis trial
Newton, Massachusetts-based Karyopharm Therapeutics (Nasdaq: KPTI) reported that selinexor (Xpovio) combined with ruxolitinib nearly doubled the spleen...
Praxis considering vormatrigine future after Phase II/III endpoint miss in focal onset seizures
Praxis Precision Medicines (Nasdaq: PRAX) reported that the Phase II/III POWER1 study of vormatrigine in adults with focal onset seizures did not meet its...
Abivax dismisses cancer fears as obefazimod meets primary endpoint in Phase III ulcerative colitis maintenance trial
Abivax SA (Euronext Paris: ABVX / Nasdaq: ABVX) reported that obefazimod, its oral once-daily miR-124 enhancer, met the primary endpoint and all key...
Astellas terminates Phase I for KaliVir-licensed oncolytic vaccinia virus
Astellas Pharma Global Development, Inc. has terminated its Phase I clinical trial of ASP1012, an engineered oncolytic vaccinia virus, in adults with...
Oculis' lead candidate fails to meet primary endpoint in Phase III diabetic macular edema trials
Oculis Holding AG (Nasdaq: OCS) reported that OCS-01, its topical eye drop formulation under investigation for diabetic macular edema, failed to meet the...
ASCO: Revolution Med posts full Phase III pancreatic cancer data set for daraxonrasib
Revolution Medicines (Nasdaq: RVMD) reported Phase III data showing that daraxonrasib, an oral RAS(ON) multi-selective inhibitor, cut the risk of death by...
The AllSci Brief
Systematic R&D and deal news. Daily.